首創鉅大(01329.HK)2023年淨利潤1376.1萬元 同比扭虧為盈
格隆匯2月27日丨首創鉅大(01329.HK)公吿,截至2023年12月31日止12個月,集團的收入約為人民幣21.2億元,較2022年同期經重列的人民幣9.36億元增加127%。集團的期間淨利潤約為人民幣1376.1萬元,較2022年同期的期間虧損人民幣3.93億元增加103%。每股基本盈利0.33人民幣分。
收入增加主要由於年度在建物業完工導致物業銷售收入大幅增加,以及自新冠疫情防控政策優化以來,奧特萊斯銷售業績大幅提升。集團本期實現扭虧為盈的主要原因包括集團的投資物業的公允價值收益較上年同期相比明顯增加,以及因出售武漢和濟南兩個奧萊項目確認收益所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.